‘Stivarga Tab’ settled by RSA, becoming the 10th
The risk sharing agreement(RSA) for Stivarga Tab, a Bayer’s regorafenib gastrointestinal tumor treatment was settled. Thus, it became the 10th RSA-applied drug, starting with Evoltra Inj on December 2013.
The National Health Insurance Service(NHIS) and Bayer settled the RSA for Stivarga Tab. The...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
